207  OnabotA for CM: benefits beyond headache-day reduction. Issue 6 (27th May 2022)

• Record Type: Journal Article
• Authors: Blumenfeld, Andrew M; Diener, Hans-Christoph; Lipton, Richard B; Dodick, David W; DeGryse, Ronald E; Adams, Aubrey Manack; Sommer, Katherine; Silberstein, Stephen D
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 93:Issue 6(2022)
• Page Start: A73
• Page End: A73
• Publication Date: 2022-05-27
• Subjects: Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2022-ABN.236
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Objective: Evaluate the impact of onabotulinumtoxinA treatment in adults with chronic migraine. Methods: Post-hoc analysis of pooled data from the 24-week, placebo-controlled, PREEMPT (NCT00156910, NCT00168428 ) and single-arm, 108-week COMPEL (NCT01516892 ) studies. Percentages of participants meeting responder status at 24, 48, or 108 weeks for clinically meaningful changes in headache days (≥50% reduction), Headache Impact Test (HIT-6; ≥5-point improvement), Migraine-Specific Quality-of-Life Questionnaire Role Function-Restrictive (MSQ-RFR; ≥10.9-point improvement), and either Average Daily Headache Severity (ADHS; ≥1-point improvement; PREEMPT) or Migraine Disability Assessment Scale (≥5-point improvement) were calculated. Results: Participants (N=1384) were randomized to onabotulinumtoxinA (n=688) or placebo (n=696) in PREEMPT; 716 participants were enrolled in COMPEL. In PREEMPT, significantly more participants treated with onabotulinumtoxinA than placebo met responder criteria for change in headache days (44.8% vs 34.2%), HIT-6 (40.8% vs 25.3%), MSQ-RFR (59.0% vs 40.2%), and ADHS (35.5% vs 22.4%) scores at 24 weeks (all P<0.001). At least 1 domain was met by 72.1% and 56.6% of PREEMPT participants treated with onabotu- linumtoxinA and placebo, respectively (P<0.001), and 87% of onabotulinumtoxinA-treated participants at year 2 in COMPEL. Conclusions: OnabotulinumtoxinA-treated participants demonstrated clinically meaningful improvements across multiple domains in the PREEMPT studies and up to 2 years in COMPEL. [e-mail]